Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 69

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 3
Chunk 69
---
 and the timing of any such sales, are at our complete discretion and we are under no obligation to sell any shares of
Common Stock to Yorkville under the SEPA.

The
price of our Common Stock could decline if there are substantial sales of shares of our Common Stock, if there is a large number of shares
of our Common Stock available for sale, or if there is the perception that these sales could occur.

Any
issuance of shares of Common Stock pursuant to the SEPA, if not terminated and if and when available, whether upon conversion by Yorkville
of a Convertible Note or upon issuance of common shares in the form of an Advance, will dilute the percentage ownership of our stockholders
and may dilute the per share projected earnings (if any) or book value of our Common Stock. Sales of a substantial number of shares of
our Common Stock in the public market or other issuances of shares of our Common Stock, or the perception that these sales or issuances
could occur, could cause the market price of our Common Stock to decline and may make it more difficult for you to sell your shares at
a time and price that you deem appropriate.

The
actual number of shares of Common Stock we will issue pursuant to the SEPA, if not terminated and if and when available, at any one time
or in total, is uncertain.

Subject
to certain conditions in the SEPA, if not terminated and if and when available, and subject to compliance with applicable law, we have
issued Convertible Notes to Yorkville, which may be converted into shares of our Common Stock at any time and from time to time during
the term of the Convertible Notes, and we may also issue additional shares of our Common Stock to Yorkville in connection with Advances
under the SEPA. The number of shares of Common Stock that are issued to Yorkville will fluctuate based on a number of factors. It is
not possible at this stage to predict the number of shares of Common Stock that will be ultimately issued pursuant to the SEPA, if not
terminated and if and when available.

Outstanding
amounts under the SEPA, if not terminated and if and when available, will make us more vulnerable to downturns in our financial condition,
and any shares of Common Stock we issue under the SEPA, if not terminated and if and when available, will further dilute our stockholders.

As
of the date of this Quarterly Statement on Form 10-Q, there are $4